Anti-TIGIT inhibitors plus PD-1 or PD-L1 inhibitors versus PD-1 or PD-L1 inhibitors for first-line treatment of advanced non-small cell lung cancer
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the effectiveness and safety of anti-TIGIT inhibitors in combination with PD-1 inhibitors or PD-L1 inhibitors compared to treatment with PD-1 inhibitors or PD-L1 inhibitors in the first-line treatment of advanced NSCLC. To assess the effectiveness and safety of anti-TIGIT inhibitors in combination with chemotherapy and PD-1 inhibitors or PD-L1 inhibitors compared to treatment with chemotherapy plus PD-1 inhibitors or PD-L1 inhibitors in the first-line treatment of advanced NSCLC.
Authors
- Jinhui Tian (ORCID: https://orcid.org/0000-0002-7082-3569)
- Xiajing Chu (ORCID: https://orcid.org/0000-0002-6283-8074)
- Ya Gao
- Fanqi Wu (ORCID: https://orcid.org/0000-0002-5267-2322)
- Lun Li (ORCID: https://orcid.org/0009-0000-3544-753X)
- Liang Yao (ORCID: https://orcid.org/0000-0003-4068-3136)
- Ming Liu (ORCID: https://orcid.org/0000-0002-9649-6025)
- Long Ge (ORCID: https://orcid.org/0000-0002-3555-1107)
Institutions
- Central South University (CN)
- Shandong University (CN)
- Nanyang Technological University (SG)
- Lanzhou University Second Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- Impact (CA)
- Lanzhou University (CN)
- McMaster University (CA)
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1002/14651858.cd015888
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00